Mats Wahlstrom - 12 Jun 2025 Form 4 Insider Report for Coherus Oncology, Inc. (CHRS)

Role
Director
Signature
/s/ Bryan McMichael, as Attorney-in-Fact for Mats Wahlstrom
Issuer symbol
CHRS
Transactions as of
12 Jun 2025
Net transactions value
$0
Form type
4
Filing time
13 Jun 2025, 18:49:51 UTC
Previous filing
28 May 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Wahlstrom Mats Director C/O COHERUS ONCOLOGY, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY /s/ Bryan McMichael, as Attorney-in-Fact for Mats Wahlstrom 13 Jun 2025 0001459154

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CHRS Stock Option (Right to Buy) Award $0 +112,000 $0.000000 112,000 12 Jun 2025 Common Stock 112,000 $0.7904 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the one year anniversary of June 11, 2025, subject to Reporting Person's continued service relationship with the Issuer on such vesting date.